Endocyte Annual Revenue, Competitors, Number of Employees and Funding

Claim your profile

Overview

Location:
West Lafayette, IN USA
Total Funding:$160M
Industry:Pharma
Founded:1996
Lead Investor(s):Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc
Press
Claim your profile

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Endocyte's estimated annual revenue is currently $15.9M per year.
  • Endocyte received $101.8M in venture funding in April 2014.
  • Endocyte's estimated revenue per employee is $201,000
  • Endocyte's total funding is $160M.

Employee Data

  • Endocyte has 79 Employees.
  • Endocyte grew their employee count by 20% last year.
  • Endocyte currently has 1 job openings.

Executive Contacts

NameTitleEmail
Karen HilbertManager, Financial Clinical OperationsEmail Available
Iontcho VlahovVp Discovery ChemistryEmail Available
Matthew CallCOOEmail Available
Lindsay WillardFinancial Planning ManagerEmail Available
Ryan DortonDirector, Discovery OperationsEmail Available
Lisa CoyClinical Data ManagerEmail Available
Sheila SwainAssociate Director Of Clinical QualityEmail Available
Anita MatthewsClinical Quality Manager
Wendy PerezDirector of Clinical Operations at Endocyte, Inc.Email Available
Beth TaylorVice President, Finance and Chief Accounting Officer

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

79

Number of Employees

$15.9M

Revenue (est)

1

Current Jobs

20%

Employee Growth %

$160M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
AIT Bioscience
$12.3M6113%N/A
GrandView Pharm...
$17.7M887%N/A
Endocyte
$15.9M7920%N/A
Singota Solutio...
$8.4M425%N/A
SSCI, a Divisio...
$8.6M438%N/A
MedScript LTC P...
$7.4M3728%N/A
Missing a competitor? Contribute!?
Submit

Endocyte News

09/09/2019 - Global Cancer Tubulin Inhibitors Market Volume Analysis ...

Major Players in Cancer Tubulin Inhibitors Market are Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...

08/20/2019 - Global Cancer Tubulin Inhibitors Market 2019 – Abraxis ...

The major player of the Cancer Tubulin Inhibitors market (Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...

08/13/2019 - iTeos Therapeutics Announces Appointment of Matthew Call ...

During his 16 year tenure at Endocyte, he had responsibility for all business development and strategic transactions and led a variety of ...

Endocyte Funding

DateAmountRoundLead InvestorsReference
2004-11-22$3.5MUndisclosedArticle
2004-12-07$23.0MC-2Burrill and CompanyArticle
2006-11-14$30.0MDArticle
2007-03-26$15.0MC3Article
2008-02-06$15.0MUndisclosedOxford Finance Corp, GE Healthcare Financial ServicArticle
2009-10-19$26.0MCSanderling Ventures, Burrill & CompanyArticle
2010-09-01$15.0MUndisclosedMidCap Financial, Silicon Valley BankArticle
2011-08-04$66.8MUndisclosedArticle
2014-03-27$UndisclosedUndisclosedCredit Suisse Securities (USA) LLCArticle
2014-04-04$101.8MUndisclosedArticle

Endocyte Executive Hires

DateNameTitleReference
2012-07-27David MeekChief Commercial OfficerArticle
2013-04-26Torsten HoofVP/General Manager EuropeArticle
2013-05-08Scot L. HarperVP Clinical OperationsArticle
2015-04-08David MozleyVP ImagingArticle
2016-06-21Mike ShermanPresident/CEOArticle
2017-02-22Michael AndrioleChief Financial OfficerArticle